This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Falk, R.
Right arrow Articles by Polacheck, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Falk, R.
Right arrow Articles by Polacheck, I.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2004, p. 3606-3609, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3606-3609.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Distribution of Amphotericin B-Arabinogalactan Conjugate in Mouse Tissue and Its Therapeutic Efficacy against Murine Aspergillosis

Rama Falk,1 Jacob Grunwald,2 Amnon Hoffman,3 Abraham J. Domb,2 and Itzhack Polacheck1*

Department of Clinical Microbiology and Infectious Diseases, The Hebrew University-Hadassah Medical Center,1 Departments of Medicinal Chemistry,2 Pharmaceutics, The Hebrew University of Jerusalem-School of Pharmacy, Jerusalem, Israel3

Received 15 April 2004/ Returned for modification 18 April 2004/ Accepted 29 April 2004

The pharmacokinetic characteristics and tissue distribution of a novel water-soluble, nontoxic amphotericin B-arabinogalactan (AMB-AG) conjugate exhibited distinct differences from those of micellar and liposomal amphotericin B formulations. These differences included extended persistence of drug in the body and its accumulation in the lungs; thus, the AMB-AG conjugate was highly effective in treating systemic murine aspergillosis.

* Corresponding author. Mailing address: Department of Clinical Microbiology and Infectious Diseases, The Hebrew University-Hadassah Medical Center, P.O. Box 12000, Jerusalem 91120, Israel. Phone: 972-2-6776592. Fax: 972-2-6419545. E-mail: Itzhack.Polacheck{at}huji.ac.il.

Antimicrobial Agents and Chemotherapy, September 2004, p. 3606-3609, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3606-3609.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Gershkovich, P., Wasan, E. K., Lin, M., Sivak, O., Leon, C. G., Clement, J. G., Wasan, K. M. (2009). Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother 64: 101-108 [Abstract] [Full Text]  
  • Seifert, K., Croft, S. L. (2006). In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs. Antimicrob. Agents Chemother. 50: 73-79 [Abstract] [Full Text]  
  • Falk, R., Hacham, M., Nyska, A., Foley, J. F., Domb, A. J., Polacheck, I. (2005). Induction of interleukin-1{beta}, tumour necrosis factor-{alpha} and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan. J Antimicrob Chemother 55: 713-720 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»